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Scope: Several methods are used worldwide for antibiotic susceptibility testing (AST) for the Mycobac-
terium tuberculosis complex (MTBC). The variability in the results obtained with these methods hampers
setting epidemiological cut-off (ECOFF) values and clinical breakpoints according to EUCAST guidelines.
Methods for susceptibility testing and determination of the minimal inhibitory concentrations (MICs)
need to be standardized for MTBC isolates for old and new agents. Our objective was to establish a
standardized reference method for MIC determination for MTBC.
Methods: The EUCAST antimycobacterial susceptibility testing subcommittee (AMST) compared pro-
tocols of MIC determination with regard to medium, inoculum preparation, antituberculous agent
preparation, incubation, reading of the results and interpretation.
Recommendations: The EUCAST reference method of MIC determination for MTBC is the broth micro-
dilution method in Middlebrook 7H9-10% OADC medium. The final inoculum is a 105 CFU/mL suspension,
obtained from a 102 dilution of a 0.5 McFarland suspension prepared after vortexing bacterial colonies
with glass beads before suspending them in sterile water. The culture is maintained in a U-shaped 96-
well polystyrene microtitre sterile plate with a lid incubated at 36 ± 1C. Reading is done using an
inverted mirror as soon as the 1:100 diluted control (i.e. 103 CFU/mL suspension) shows visual growth.
The MIC, expressed in mg/L, is the lowest concentration that inhibits visual growth. Mycobacterium
tuberculosis H37Rv ATCC 27294 is used as the reference strain and its targeted MIC values are within the
range 0.03e0.12 for isoniazid, 0.12e0.5 for levofloxacin and 0.25e1 mg/L for amikacin.
Conclusions: The EUCAST reference method for MTBC was endorsed by EUCAST after public consultation
and will from now on be used to define EUCAST ECOFFs and clinical breakpoints. This reference method
is not primarily intended to be used under routine conditions and the AST methods will need to beice de Bacteriologie, Ho^pital Lariboisiere, 2 rue Ambroise-Pare, Paris, 75010, France.
ambau).
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Since the first antimicrobials were introduced in the treatment
of tuberculosis (TB), determinations of minimal inhibitory con-
centrations (MICs) were performed before human use in order to
assess in vitro activity against isolates of the Mycobacterium tuber-
culosis complex (MTBC) [1] or in parallel with therapeutics to detect
isolates that developed acquired resistance [2]. Although the MIC
definition is internationally recognized for all bacteria as the lowest
concentration (expressed in mg/ml or mg/L) inhibiting visual
growth compared with a drug-free growth control under the same
test conditions, many different methods have been used in the case
of antituberculous agents with regards to the inoculum, the me-
dium and the reading endpoints [3]. MIC determination is also a
tool used to assess the distribution of clinical isolates according to
the antibacterial activity, and such distribution is needed to char-
acterize the epidemiological cut off value (ECOFF). The ECOFF is
defined as the highestMIC valuemeasured for phenotypically wild-
type isolates, i.e. those without acquired mechanisms of resistance
[4]. In the TB field, for the first antituberculous agents such as
isoniazid, critical concentrations (CCs) were experimentally deter-
mined on microbiological and clinical evidence but mainly on egg-
based medium that was used at that time [1]. Several antimicrobial
susceptibility testing (AST) methods have been developed since the
1960s to separate susceptible (no growth in presence of the anti-
microbial agent at CC) and resistant (growth at CC) isolates [3,5].
Many different strategies for AST of MTBC are still used worldwide
without reaching a consensus [5], a situation that has complicated
methodological standardization and generated several breakpoints
per agent [6]. However, clinical breakpoints (CBs), as defined for
other antimicrobials, are relying also on clinical parameters such as
pharmacokinetics, pharmacodynamics and treatment outcome.
Consequently, CBs should not be dependent on variability with
regard to the methods used for AST.
For new antimicrobial agents, EUCAST breakpoints are
established during the marketing authorization process con-
ducted by European Medical Agency (EMA) and its Committee for
Medical Products for Human Use (CHMP). In 2011, EMA
approached EUCAST for determining breakpoints of the new
antituberculous drugs, delamanid and bedaquiline, and EUCAST
asked the ESCMID study group of mycobacterial infections
(ESGMYC) for assistance. The lack of a uniform and standardized
reference method for MIC determination of MTBC became
obvious as different methods were used during this process.
There were inconsistent data to set proper ECOFFs, confusion
about which MIC method to use for PK/PD studies and difficulties
with evaluating the level of resistance causing treatment
outcome failure [7]. Because of the limited MIC data obtained
from several non-standardized methods, provisory breakpoints
were set as concentrations of 0.06 mg/L for delamanid and 0.25
mg/L for bedaquiline (www.eucast.org).
In 2016, the EUCAST subcommittee for antimycobacterial drug
susceptibility testing (AMST) was launched with a primary goal of
defining a reference method for MIC determination on the MTBC.
Detailed protocols for MIC determination in solid medium (agar
dilution in Middlebrook 7H10) and in liquid culture (brothmicrobial susceptibility testin
termination, Clinical Microbiomicrodilution in Middlebrook 7H9) were developed and evaluated
for reproducibility in a multicentre study for which the results are
reported elsewhere.
The aim of this paper is to describe the final protocol for the
referencemethod, addressing some of the questions and comments
received during the public consultation. The reference method is
intended to be practised without commercial restrictions.
Scope
The EUCAST AMST subcommittee wishes to make the following
clarifications regarding the proposed reference MIC method for
MTBC. The proposed reference methoddbroth microdilution in
Middlebrook 7H9 mediadwas set based on the results from a
multicentre study of reproducibility, described elsewhere (Schon
et al. [16]) and other considerations such as labour requirements,
cost and non-commercially based. The technical protocol was
available for consultation during 6 weeks (from 15 of May to 26 of
June, 2019) and then presented to the EUCAST steering committee
for a formal decision after considering the necessary amendments
resulting from the consultation. The test protocol was published on
the EUCAST website on the 19 of July in 2019 as the EUCAST
reference method for MIC determination on MTBC (http://www.
eucast.org/documents/consultations/).
The EUCAST reference MIC method is not intended primarily for
use in clinical microbiology routine. Within EUCAST, it will be the
only method used for defining ECOFFs and clinical breakpoints for
MTBC, but other AST methods may be used with EUCAST clinical
breakpoints as long as they are calibrated according to the EUCAST
AMST recommendations (www.eucast.org). The calibration stan-
dard of procedures (SOP) specifies the requirements and steps for
calibrating clinically used methods, commercially based or not,
against the EUCAST reference method.
EUCAST reference method for MIC determination of
antimicrobial agents for M. tuberculosis complex: standard of
procedure
The EUCAST reference method is a broth microdilution method
similar to EUCAST reference methods for other bacteria and fungi
with the exception of the media used, inoculum preparation and
time of incubation. The main parameters are described in the
Table 1. AllM. tuberculosis cultures should be maintained according
to existing biosafety guidelines [8,9].
Medium
The medium chosen is the commonly used synthetic rich me-
dium, Middlebrook 7H9 (7H9), developed by Dubos and Mid-
dlebrook in 1947 [10e12]. Before use, it should be supplemented by
a mixture of oleic acid, albumin, dextrose and catalase (OADC),
available ready to use. Both Middlebrook 7H9 medium and OADC
enrichment are available from at least three different manufac-
turers, as requested by EUCASTguidelines [4]. After the 7H9 broth is
prepared from the base according to the manufacturer's in-
structions and autoclaved, OADC (pre-warmed to roomg ofMycobacterium tuberculosis complex isolates e the EUCAST broth
logy and Infection, https://doi.org/10.1016/j.cmi.2020.07.036
Table 1
Summary of the EUCAST ASMT reference method standard operational procedures (SOP) for MIC determination of antituberculous agents
Parameters EUCAST AMST SOP Comment
Medium Middlebrook 7H9 þ 10% OADC
Plate U-shaped polystyrene microtitre sterile plate Covered by a lida
Pre-culture Solid media: egg based (LJ, Coletsos …) or synthetic (7H10, 7H11) Harvest colonies no later than 2 weeks after visible growth
Inoculum 102 dilution of a McF 0.5 suspension prepared by two steps dilution 105 CFU/mL final concentration
Incubation 36 ± 1C up in ambient air Plates are placed in a specific box with sterile water
Reading Visual reading using an inverted mirror In safety cabinets and following BSL3 safety measures
Time of reading As soon as the 1:100 diluted control (i.e. 103 CFU/mL) shows visual growth Between 7 and 21 days
Report of MIC Lowest concentration where no visual growth Value in mg/L
Quality control Mycobacterium tuberculosis H37Rv ATCC 27294 Isoniazid MIC: 0.03e0.12
Levofloxacin MIC: 0.12e0.5
Amikacin MIC: 0.25e1
a Sealing with a plastic sheet was not tested and should be calibrated if preferred.
T. Sch€on et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3temperature, 18e22C) is added only when 7H9 has reached 50C
in a pre-warmed water bath. For each 96-well microtitre plate, 10
mL of the ready-made 7H9-OADC broth is needed.Preparation of the antituberculous agents
All drug solutions should be prepared according with the Good
Manufacturing Practice and powders must be obtained directly
from the drug manufacturer or from reliable commercial sources
together with appropriate documentation for quality assurance.
Generally, drugs should be dissolved as described in ISO-20776-1
guidelines or if not listed per recommendation of the manufac-
turer (see examples in Table 2). Since many antituberculous drugs
are not soluble in water, the solvent should be used with caution
with regard to its own potential inhibitory effect against MTBC.
Consequently, for solvents other than water such as dimethyl
sulphoxide (DMSO), there should be growth controls containing
the same proportion of solvent (e.g. in case of DMSO) as the drug-
containing medium, and the concentration of the solvent should be
the same for all concentrations.
A stock solution should be prepared as outlined in Table 2, and
then aliquoted into 0.2-mL vials, stored at e20C or e80C as rec-
ommended in the CLSI guidelines [12] unless otherwise specified
by the manufacturer. Thawed vials should not be re-used. Order
and batch number of all agents as well as the date of stock solution
preparation should be recorded.
The 4 working solution is prepared with two dilution steps in
7H9-OADC from an aliquot of a stock solution as outlined in Table 2
(example given for isoniazid, levofloxacin and amikacin). The
addition of OADC is not necessary for preparing the first working
solution but it is necessary for the subsequent dilution step since
this will be the final medium solution in which the mycobacteria
will grow.Table 2
Examples of preparation of antituberculous agents that were evaluated using the referen
Antimicrobial agent Sigma ref. for drug
powder no.
Solvent Stock concb (mg/L) Dilution
Isoniazid I3377 dH20 10 240 1:64
Amikacin A1774 dH20 10 240 1:64
Levofloxacin 28266 NaOHa 10 240 1:64
a Add powder to 50% dH2O of the total volume and then 1 mol/L NaOH dropwise to d
b Calculate the amount of drug to dissolve in 10 mL according to potency: m, V*p/P; m,
in mg/L; P, potency of the antimicrobial agent (powder) in mg/g (i.e. 67% potency means
potency is not specified by the manufacturer, it may be calculated by (assay purity)  (ac
100% active fraction the potency is (998)  (1.0)  (1e 0.121) ¼ 877 mg/mg or 87.7%.
c The addition of OADC is not necessary in this step as it is for further dilution only.
d 1 mL is needed for ten plates.
Please cite this article as: Sch€on T et al., Antimicrobial susceptibility testin
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A sterile 96-well U-bottom-shaped polystyrene microtitre
plate should be used. Plates made of polypropylene or other
plastic material should not be used since mycobacteria and some
antituberculous drugs can adhere to the plastic and consequently
the concentration may be artificially reduced. When the plates
have been prepared, they should be used as soon as possible and
within the same day, because the microtitre plates will be incu-
bated for several days at 36C ± 1C and some of the drugs may be
inactivated or degraded with regard to the length of the incuba-
tion time. MIC determination of each agent should be done by
testing at least eight concentrations in separated wells to cover
the full range of potential MIC values (outlined in Table 2 and
Fig. 1) with at least one concentration below and one above the
MIC target. ECOFFs and breakpoints cannot be established using
off-scale MIC values below or above a truncated range of con-
centrations [13].
As described in the Fig. 1, the wells are filled with 0.1 mL of
7H9-OADC, except the peripheral wells, which are filled with
sterile distilled water in order to prevent desiccation during the
incubation time. Then, following the plate outline in Fig. 1, 0.1 mL
of the 4 working solution, which corresponds to the highest
concentration of each agent, is added to the left row. It should be
ensured that no agent is added to the negative and growth
control (GC) wells. In most cases, a multichannel pipette can be
used to make 1:2 dilutions from the highest concentration row to
the following row and finally discard the last 0.1 mL of the last
row. However, it should be noted that this step is not adequate
for the agents for which the solvent should be kept at the same
minimum concentration (e.g. 1% DMSO). In this case, the agent
working solutions should be diluted separately and each dilution
added one by one to the corresponding wells in the microtitre
plate.ce protocol by EUCAST-AMST againstMycobacterium tuberculosis H37Rv ATCC 27294
1 (7H9)c Dilution 2 (7H9/OADC) Working conc. in
7H9/OADC (mg/L)d
Range of final
concentrations (mg/L)
1:40 4 1e0.008
1:5 32 8e0.06
1:10 16 4e0.03
issolve. Then add dH2O to the final volume.
mass of the antimicrobial agent (powder) in g; p, concentration of the stock solution
670 mg/g or and 100% potency 1000 mg/g); V, volume of solvent in litre. In case the
tive fraction)  (1 e water content), i.e. for a 99.8% purity, 12,1% water content and
g ofMycobacterium tuberculosis complex isolates e the EUCAST broth
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 1 2 3 4 5 6 7 8 9 10 11 12
A 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 
dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20
B negative GC AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) GC 200ul 
 control 100% C8 C7 C6 C5 C4 C3 C2 C1 1% dH20
C negative GC AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) AA1 (10-2) GC 200ul 
 control 100% C8 C7 C6 C5 C4 C3 C2 C1 1% dH20
D negative GC AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) GC 200ul 
control 100% C8 C7 C6 C5 C4 C3 C2 C1 1% dH20
E negative GC AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) AA2 (10-2) GC 200ul 
control 1% C8 C7 C6 C5 C4 C3 C2 C1 100% dH20
F negative GC AA3 (10-2) AA3 (10-2) AA3 (10-2) AA3(10-2) AA3 (10-2) AA3 (10-2) AA3 (10-2) AA3 (10-2) GC 200ul 
 control 1% C8 C7 C6 C5 C4 C3 C2 C1 100% dH20
G negative GC AA3 (10-2) AA3 (10-2) AA3 (10-2) AA3(10-2) AA3 (10-2) AA3 (10-2) AA3 (10-2) AA3 (10-2) GC 200ul 
 control 1% C8 C7 C6 C5 C4 C3 C2 C1 100% dH20
H 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 200ul 
dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20 dH20
Fig. 1. Scheme of the microtitre plate for the EUCAST AMST broth microdilution reference protocol. AA1, antituberculous agent 1 to be tested; AA2, antituberculous agent 2; AA3,
antituberculous agent 3; GC, growth control; 100% corresponds to the same inoculum as in the drug containing wells; 1% corresponds to the hundredfold diluted inoculum;
negative control is 200 mL of 7H9-OADC; dH20, sterile distilled water.
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This preparation is a critical step for repeatability and repro-
ducibility since MTBC cultures are spontaneously aggregating,
which results in uneven distribution of bacterial cells in the inoc-
ulum and dilutions with uncertain final numbers of bacterial cell
per millilitre. Tween-80 should not be used as it may affect the drug
penetration into the mycobacterial cell wall and potentially reduce
the MIC value [14].
For pre-culture, MTBC isolates should be grown on solid media
(7H10 or 7H11 Middlebrook agar, L€owensteineJensen or other egg-
based solid media) and sampled from fresh cultures (within
2 weeks after appearance of visible growth). Approximately 1 mg
(four loops of 1 mL or a full 3-mm loop) of morphologically similar
colonies, to avoid selecting an atypical variant, will be mixed in a
10e15-mL sterile screw-cap glass tube containing five to ten sterile
glass beads (3 mm) after scratching them along the inside wall of
the tube using an applicator stick or plastic loop. It is important to
avoid scraping off medium. After careful closing of the cap, it is
needed to vortex at least 2 min in order to disperse the clumps
before adding any liquid. Then, 5 mL of fresh sterile distilled water
should be added, the cap is closed tightly and the tube's content
homogenized by vigorously vortexing the tube to swirling for at
least 2 min. It is necessary to wait 30 min for the remaining clumps
to settle. Adjust the turbidity of the supernatant in a new glass tube
to McFarland 0.5 by adding sterile distilled water, and vortex for
30 s. If the suspension density is above Mac Farland turbidity
standard (McF) 0.5, add sterile distilled water until it is reached. If
the suspension density is belowMcF 0.5, it is required to start again
from the colonies mixed with dry glass beads; otherwise, colonies
will not be sufficiently dissociated. The turbidity of the suspension
should be determined using a routine suspension turbidity meter
and not by visual estimation.Preparation of the inoculum dilutions
A 1:100 dilution of the bacterial suspension in 7H9-OADC broth
is prepared in two steps of tenfold dilution. The volume of bacterial
suspension required for one 96-well microplate is 10 mL. Prepare a
101 suspension by adding 1mL of the 0.5McF bacterial suspension
to 9 mL of 7H9-10% OADC and vortex for at least 30 s until swirlingPlease cite this article as: Sch€on T et al., Antimicrobial susceptibility testin
microdilution reference method for MIC determination, Clinical Microbiois obtained. For the 102 inoculum, add 1mL of the 101 suspension
to 9 mL of 7H9-OADC. The 102 suspension will be the growth
control (GC100%), whereas a 104 suspension should be addition-
ally prepared (also in two dilution steps: 1þ9mL for the 103, then
1þ9mL for the 104 suspension). The 104 suspensionwill be used
as a second growth control (GC1%) for checking the inoculum size
and assist in accurately assessing the MIC values.
Controls of the inoculum size
The target is 1  105 CFU/mL from the 102 dilution of 0.5 McF
with an acceptable range from 5 104 to 5 105 CFU/mL for a valid
test. The inoculum size is checked by CFU counting on Middlebrook
7H10 agar after plating 10 mL of the 102 suspension (should grow
500e5000 CFU, i.e. confluent growth), 10 mL of 103 (50e500 CFU)
and 10 mL of 104 (5e50 CFU) and reading after 21 days' incubation
at 36C ± 1C. The CFU counting results should be recorded. Plating
of control suspensions is better done in duplicate or triplicate for an
accurate estimation of the inoculum size.
Inoculation of the microplate
Each antibiotic containing well is complementary filled with 0.1
mL of the 102 suspension starting by the lowest dilution. The
growth controls (GC100% and GC1%) should then be inoculated as
outlined in Fig. 1.
Incubation
After inoculation, the plate is covered with the plastic lid pro-
vided with the sterile microtitre plate and put in a O2/CO2-
permeable plastic bag or a specific box where a maximum of three
plates can be stored on top of each other. Incubation conditions for
maintaining a temperature of 36C ± 1C and adequate ventilation
should be regularly checked. Of notice, the use of plastic sheet
sealing was not tested in this protocol and therefore cannot be used
without a proper calibration.
Reading and interpretation of results
The plates should be read using an inverted mirror to detect
positive and negative growth in the wells. Systematic readingg ofMycobacterium tuberculosis complex isolates e the EUCAST broth
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T. Sch€on et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 5should be scheduled after 7 and 14 days of incubation. If there is
still insufficient growth of the GC1% after 14 days, the incubation
can last until a maximum of 21 days. As soon as the GC100% and the
GC1% are positive (GC1% shows weaker positivity than GC100%),
MIC can be determined as the lowest concentration where no
visible growth is observed. The 7H9 negative control should show
no growth for the test to be valid. Report the MIC value in mg/L.Quality controls
The fully drug-susceptible M. tuberculosis H37Rv ATCC 27294
reference strain should be included in each testing round and the
same aliquot should not be used beyond five subculture passages.Limitations
The intended use of this protocol is MIC determination, pri-
marily for M. tuberculosis isolates. Although M. tuberculosis is the
species most frequently involved in human tuberculosis, the
M. tuberculosis complex comprises other species, such as M. bovis,
M. africanum andM. canettii, and variants such asM. bovis BCG and
several lineages of M. tuberculosis [15]. These species and lineages
may have specificcharacters, such as intrinsic pyrazinamide resis-
tance of M. bovis BCG, or the extra slow growth of M. africanum.
Consequently, testing strains of these different species and lineages
might require amendments to the protocol. Another limitation is
that some antituberculous agents may require separate consider-
ations due to their dissolution, stability at 36C or other factors.
These modifications of the protocol will require constant updates
and addenda through the interaction with the EUCAST AMST.Transparency declaration
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